Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan's MHLW Council Approves Merck's Sitagliptin

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Health, Labor and Welfare approved Merck's sitagliptin for type II diabetes July 24. The first committee of the Pharmaceutical Affairs And Food Sanitation Council cleared the first dipeptidyl-peptidase IV inhibitor in Japan. Sitagliptin will be manufactured and marketed by Merck Japan licensing partner Ono Pharmaceutical, and manufactured and marketed under Januvia by Merck Japan unit Banyu Pharmaceutical. The market exclusivity time is 8 years. The final approval is expected to be handed out in September. Sitagliptin is currently approved in over 80 countries. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts